BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 14709288)

  • 21. Brimonidine tartrate: a one-month dose response study.
    Derick RJ; Robin AL; Walters TR; Barnebey HS; Choplin N; Schuman J; Kelley EP; Chen K; Stoecker JF
    Ophthalmology; 1997 Jan; 104(1):131-6. PubMed ID: 9022117
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brimonidine 0.2% versus brimonidine Purite 0.15%: prophylactic effect on iop elevation after Nd:YAG laser posterior capsulotomy.
    Yeom HY; Lee JH; Hong YJ; Seong GJ
    J Ocul Pharmacol Ther; 2006 Jun; 22(3):176-81. PubMed ID: 16808678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brinzolamide-brimonidine fixed combination for the prevention of intraocular pressure elevation after phacoemulsification.
    Georgakopoulos CD; Kagkelaris K; Pagoulatos D; Plotas P; Makri OE
    Eur J Ophthalmol; 2020 Mar; 30(2):293-298. PubMed ID: 30526051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of intracameral acetylcholine on latanoprost in preventing ocular hypertension after phacoemulsification and intraocular lens implantation.
    Lai JS; Chua JK; Loo A; Ho SY; Lam DS
    J Cataract Refract Surg; 2001 May; 27(5):700-5. PubMed ID: 11377899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of latanoprost, bimatoprost, and travoprost on intraocular pressure after cataract surgery.
    Arici MK; Erdogan H; Toker I; Vural A; Topalkara A
    J Ocul Pharmacol Ther; 2006 Feb; 22(1):34-40. PubMed ID: 16503773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of 0.2% brimonidine in preventing intraocular pressure elevation after Nd:YAG laser posterior capsulotomy.
    Seong GJ; Lee YG; Lee JH; Lim SJ; Lee SC; Hong YJ; Kwon OW; Kim HB
    Ophthalmic Surg Lasers; 2000; 31(4):308-14. PubMed ID: 10928668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of brimonidine on aqueous humor dynamics in human eyes.
    Toris CB; Gleason ML; Camras CB; Yablonski ME
    Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fixed combination brimonidine-timolol versus brimonidine for treatment of intraocular pressure elevation after neodymium:YAG laser posterior capsulotomy.
    Öner V; Alakuş MF; Taş M; Türkyılmaz K; Işcan Y
    J Ocul Pharmacol Ther; 2012 Dec; 28(6):576-80. PubMed ID: 22809091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab.
    Theoulakis PE; Lepidas J; Petropoulos IK; Livieratou A; Brinkmann CK; Katsimpris JM
    Klin Monbl Augenheilkd; 2010 Apr; 227(4):280-4. PubMed ID: 20408074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bimatoprost 0.03% versus brimonidine 0.2% in the prevention of intraocular pressure spike following neodymium:yttrium–aluminum–garnet laser posterior capsulotomy.
    Artunay O; Yuzbasioglu E; Unal M; Rasier R; Sengul A; Bahcecioglu H
    J Ocul Pharmacol Ther; 2010 Oct; 26(5):513-7. PubMed ID: 20874499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of apraclonidine versus dorzolamide on intraocular pressure after phacoemulsification.
    Onal S; Gozum N; Gucukoglu A
    Ophthalmic Surg Lasers Imaging; 2005; 36(6):457-62. PubMed ID: 16355950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
    LeBlanc RP
    Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
    Walters TR
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension.
    Stewart WC; Day DG; Stewart JA; Schuhr J; Latham KE
    Am J Ophthalmol; 2001 May; 131(5):631-5. PubMed ID: 11336939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preoperative Brimonidine Tartrate 0.2% Does not Prevent an Intraocular Pressure Rise During Prostatectomy in Steep Trendelenburg Position.
    Mathew DJ; Greene RA; Mahsood YJ; Hallaji N; Vargas AMB; Jin YP; Finelli A; Parotto M; Belkin A; Trope GE; Buys YM
    J Glaucoma; 2018 Nov; 27(11):965-970. PubMed ID: 30095608
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of brimonidine tartrate on retinal blood flow in patients with ocular hypertension.
    Carlsson AM; Chauhan BC; Lee AA; LeBlanc RP
    Am J Ophthalmol; 2000 Mar; 129(3):297-301. PubMed ID: 10704543
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brimonidine in the prevention of intraocular pressure elevation following argon laser trabeculoplasty.
    David R; Spaeth GL; Clevenger CE; Perell HF; Siegel LI; Henry JC; Stiles MC; Passo MS; Stamper RL; Walt JG
    Arch Ophthalmol; 1993 Oct; 111(10):1387-90. PubMed ID: 8105773
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. The Brimonidine Study Group III.
    Serle JB
    Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S39-47. PubMed ID: 8970248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparing brimonidine 0.2% to apraclonidine 1.0% in the prevention of intraocular pressure elevation and their pupillary effects following laser peripheral iridotomy.
    Yuen NS; Cheung P; Hui SP
    Jpn J Ophthalmol; 2005; 49(2):89-92. PubMed ID: 15838723
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prophylactic Effect of Oral Acetazolamide against Intraocular Pressure Elevation after Cataract Surgery in Eyes with Glaucoma.
    Hayashi K; Yoshida M; Manabe SI; Yoshimura K
    Ophthalmology; 2017 May; 124(5):701-708. PubMed ID: 28110949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.